Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Neutralizing antibodies
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Distributed Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 03, 2020
Details:
Under the terms of this partnership, Distributed Bio will use its SuperHuman2.0 Antibody Discovery platform to identify lead antibodies for Mediar programs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KCC2
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Kerry Murphy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing May 28, 2020
Details:
The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bispecific antibodies
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Aravive
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 30, 2020
Details:
Collaboration grants Aravive the right to use the proprietary WuXiBody™ platform to develop high-affinity bispecific antibodies for a target implicated in cancer and fibrosis.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
